New drug shows promise for spine arthritis in chinese patients
NCT ID NCT07277179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, netakimab, in 113 Chinese adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The goal was to see if netakimab works better than a placebo (a dummy treatment) at reducing symptoms. Participants received injections of either netakimab or placebo, and researchers measured improvement using standard arthritis criteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Could a simple protein test unlock the secrets of joint disease?
- Can a biologic drug safely tame Back-Joint inflammation? a Real-World trial investigates
- New antibody aims to calm ankylosing spondylitis
- Can a 4-Minute chat rival a Dietitian's hour for heart health?
- Ultrasound and EMG may tell inflammatory from mechanical shoulder issues